Noticias y eventos de Lexaria Bioscience Corp (LEXX)LEXXLexaria Bioscience Corp

Lexaria Bioscience Enters Agreement with Pharmaceutical Company

Lexaria Bioscience announces that it has entered into an Agreement with an unnamed pharmaceutical company to investigate Lexaria's DehydraTECH technology with one or more proprietary PharmCo molecules. Today's announcement is separate from, and has no relationship with, Lexaria's two Material Transfer Agreements already existing with other pharmaceutical companies. The new Agreement outlines the conditions under which PharmCo will supply Lexaria with one or more proprietary molecule which will then be processed with Lexaria's patented DehydraTECH technology for evaluation.

Selling Stockholders Plan to Sell 923,827 Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 923,827 shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Lexaria Bioscience Secures $7.9M Financing, Strong Cash Position

Lexaria Bioscience said it is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at $12.92/share. The combined net proceeds from these two items totaled $7.9M. With only 2.1M shares currently issued and outstanding, the $7.9M in fresh new capital plus our pre-existing cash balance represents approximately $4.60/share in current cash on hand. "Despite the positive achievements we have recently reported across all aspects of our business: clinical results, business development, and funding - our stock price has been under significant pressure by what can only be described as aggressive/perplexing trading activity," said Rich Christopher, CEO. "We will weather the storm and offset this predatory trading behavior through continued execution of our business strategy. We are extremely frustrated by these market conditions and are certainly thankful to our existing retail shareholder base for their patience during this trying time. The $7.9M in fresh new capital extends Lexaria's cash runway through 2027 and provides us with the strong financial footing needed to execute on our business plans. We have no intention of pursuing any additional equity or debt financings in 2026. In parallel, we have made significant progress on the business development front and as a result, we expect to spend less of our own resources to fund R&D efforts in 2027. Our intent is to continue to pursue additional business development relationships and effectively transfer certain R&D costs to our partners."